Immunovant, Inc. IMVT Income Statement
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| $142.29M+51.9% | $98.92M+4.7% | $114.25M+17.5% | $101.2M+34.1% | $93.65M+41.8% | ||
| $17.27M-14.4% | $15.44M-22.0% | $17.51M-5.2% | $26.02M+38.4% | $20.17M+36.1% | ||
| $159.55M+40.2% | $114.36M+0.1% | $131.76M+13.8% | $127.22M+34.9% | $113.83M+40.7% | ||
| $159.55M+40.2% | $114.36M+0.1% | $131.76M+13.8% | $127.22M+34.9% | $113.83M+40.7% | ||
| $8.06M+17.0% | $5.33M+16.2% | $5.6M-7.7% | $6.34M-11.7% | $6.89M-17.8% | ||
| $798K-25.5% | -$54K+95.7% | $250K-60.3% | $1.19M+4,139% | $1.07M+141% | ||
| -$150.7M-42.3% | -$109.08M+1.7% | -$125.91M-15.5% | -$119.7M-37.5% | -$105.87M-41.0% | ||
| —— | $1.55M+921% | $594K+662% | $913K+1,086% | $583K+151% | ||
| -$147.86M-38.9% | -$110.64M+0.4% | -$126.5M-15.9% | -$120.61M-38.4% | -$106.45M-41.3% | ||
| -$0.73-15.9% | -$0.61+19.7% | -$0.73+1.4% | -$0.71-18.3% | -$0.63-21.2% | ||
| -$0.73-15.9% | -$0.61+19.7% | -$0.73+1.4% | -$0.71-18.3% | -$0.63-21.2% | ||
| 182.4M+20.4% | 181.5M+23.5% | 173.6M+18.6% | 170.9M+17.0% | 151.6M+9.8% | ||
| 182.4M+20.4% | 181.5M+23.5% | 173.6M+18.6% | 170.9M+17.0% | 151.6M+9.8% | ||
| $8.06M+17.0% | $5.33M+16.2% | $5.6M-7.7% | $6.34M-11.7% | $6.89M-17.8% | ||
| $798K-25.5% | -$54K+95.7% | $250K-60.3% | $1.19M+4,139% | $1.07M+141% | ||
| $142.29M+51.9% | $98.92M+4.7% | $114.25M+17.5% | $101.2M+34.1% | $93.65M+41.8% | ||
| -$142.55M-44.2% | -$103.65M+2.5% | -$120.2M-16.8% | -$113.26M-41.9% | -$98.87M-48.4% | ||
| -$142.64M-44.1% | -$103.75M+2.5% | -$120.3M-16.8% | -$113.36M-41.9% | -$98.98M-48.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Immunovant, Inc. profitable?
- Immunovant, Inc. is not currently profitable: it reported a net loss of $505.6M over the trailing twelve months.
- What is Immunovant, Inc.'s earnings per share?
- Immunovant, Inc.'s diluted EPS over the trailing twelve months is $-2.78.
- Where does Immunovant, Inc.'s income statement data come from?
- Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.